IRB #

IRB00007677

Title

A Phase Ib Open-Label study of the Safety and Clinical Activity of Crizotinib (PF-02341066) in Tumors with Genetic Events Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus

Principal Investigator

Matthew Taylor

Study Purpose

The purpose of this study is to see whether crizotinib (the study drug) is safe and effective at slowing the growth of cancer.

Medical Condition(s)

Advanced cancer (other than non-small cell lung cancer) with a specific type of genetic makeup called an "ALK genetic event."

Eligibility Criteria

*Diagnosis of advanced malignancy (other than non-small cell lung cancer) with no standard therapy available
*Positive for ALK genetic event
*Male of female subjects at least 18 years of age
*Prior treatment must be completed at least 4 weeks before starting study drug

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until your cancer gets worse

Minors Included

No

Contact

Amy Henderson, RN
henderam@ohsu.edu
503-494-4215

Sponsor

Pfizer

Recruitment End

Compensation Provided

No